Politicians love to blame greedy Big Pharma for our country’s rapidly ballooning health care costs. But Senior Fellow Mike Mandel argues that curtailing the cost of medical labor will have the biggest impact on reducing healthcare spending.…Read More
The past year has seen several merger attempts by large pharmaceutical companies. Executive Director Saikat Chaudhuri weighs in on the motives behind these deals.…Read More
The emergence of radical technologies presents a significant challenge to incumbent firms. We study firms’ management of radical technological change by separating their actions into upstream research (“R” of R&D) and downstream development (“D” of R&D).…Read More
The pharmaceutical industry leads all industries in terms of R&D spend. Portfolio management in new drug development is extremely challenging due to long drug development cycles and high probabilities of failure.…Read More
